Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab rezetecan + fulvestrant
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
SHR-A1811 (trastuzumab rezetecan) is a third-generation antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). It consists of a humanized anti-HER2 antibody linked via a cleavable linker to a topoisomerase I inhibitor payload. The drug is designed to deliver cytotoxic agents directly to HER2-expressing tumor cells, resulting in targeted cell death. SHR-A1811 has demonstrated promising antitumor activity and acceptable tolerability in patients with HER2-positive breast cancer and other advanced solid tumors expressing or harboring mutations in HER2. Fulvestrant is an estrogen receptor antagonist used primarily for hormone receptor–positive breast cancer; the combination aims to target both HER2 and estrogen signaling pathways for enhanced efficacy in certain breast cancers[1][3][4].
- Other names
- trastuzumab rezetecan + fulvestrant
02
Targets
ESR1 (ERα)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab rezetecan + fulvestrant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab rezetecan + fulvestrant.